Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-11-10
1998-02-10
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 5, A61K 3170
Patent
active
057169373
ABSTRACT:
A method of treating cardiac malfunction by administering a positive inotropic effect-producing amount of Hypothalamic Inhibitory factor (HIF).
REFERENCES:
patent: 4551426 (1985-11-01), Freytag et al.
patent: 4665019 (1987-05-01), Hamlyn et al.
patent: 4780314 (1988-10-01), Graves
patent: 5164296 (1992-11-01), Blaustein et al.
patent: 5429928 (1995-07-01), Blausten et al.
Hunter, Meredith Mudgett et al., "High-Affinity Monboclonal Antibodies to the Cardiac Glycoside, Digoxin," The Journal of Immunology, 129(3):1165-1172 (1982).
Carilli, Cynthia T. et al., "Hypothalamic Factor Inhibits the (Na,K)ATPase from the Extracellular Surface," The Journal of Biological Chemistry, 260(2):1027-1031 (1985).
Janssens, Stefan P. et al., "Hypothalamic Na.sup.30, K.sup.30 -ATPase Inhibitor Constricts Pulmonary Arteries of Spontaneously Hypertensive Rats," Journal of Cardiovascular Pharmacology, 22(Suppl. 2):S42-S46 (1993).
Haupert, Garner T., Jr. and Sancho, Jose M., "Sodium transport inhibitor from bovine hypothalamus," Proc. Natl. Acad. Sci. USA, 76(9):4658-4660 (1979).
Haupert, Garner T., Jr. et al., "Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na.sup.+ -K.sup.+ -ATPase," reprint from American Physiological Society:F919-F924 (1984).
Mirsalikhova, N.M. et al., "Some Features of the Inhibition of Na.sup.30 ,K.sup.30 -ATPase in Heart Muscle by Cardiotonic Glycosides," Institute of Biochemistry and Institute of Chemistry of Plant Substances, Academy of Sciences and the Urbek SSR, Tashkent, USSR, pp. 269-275.
Mudgett-Hunter, Meredith et al., "Binding and Structural Diversity Among High-Affinity Monoclonal Anti-Digoxin Antibodies," Molecular Immunology, 22(4):477-488 (1985).
Smith, Thomas W. et al., "Treatment of Life-Threatening Digitalis Intoxication with Digoxin-Specific Fab Antibody Fragments," The New England Journal of Medicine, 307(22):1357-131362 (1982).
Smith, Thomas W. et al., "Reversal of Advances Digoxin Intoxication with Fab Fragments of Digoxin-Specific Antibodies," The New England Journal of Medicine, 294(15):797-800 (19767).
Hallaq, Haifa A. and Haupert, Garner T., Jr., "Positive inotropic effects of the endogenous Na.sup.+ /K.sup.+ -transporting ATPase inhibitor from the hypothalamus," Proc. Natl. Acad. Sci. USA, 86:10080-10084 (1989).
Axelrod, Julius, "J. Methylation Reactions in the Formation and Metabolism of Catecholamines and Other Biogenic Amines," Pharmacological Reviews, 18(1), Part I:95-113 (1966).
Thomas, Richard et al., "Synthesis and Biological Activity of Semisynthetic Digitalis Analogs," Journal of Pharmaceutical Sciences, 63(11):1649-1683 (1974).
Hoffman, Brian F. and Bigger, J. Thomas, Jr. "Chapter 34 Digitalis and Allied Cardiac Glycosides," in The Pharmacological Basics for Therapeutics (NY: Pergamon Press), pp. 814-839 (1990).
Sergio Bova, et al., "Effects of an Endogenous Ouabainlike Compound on Heart and Aorta," Hypertension 17(6), Part 2 pp. 944-950, Jun. 1991.
W. Rodney Mathews et al., "Mass Spectral Characterization of an Endogenous Digitalislike Factor From Human Plasma," Hypertension 17(6), Part 2, pp. 930-935, Jun. 1991.
James H. Ludens et al., "Purification of an Endogenous Digitalislike Factor From Human Plasma for Structural Analysis," Hypertension 17(6) Part 2, pp. 923-929, Jun. 1991.
J.M. Hamlyn et al., "Identification and characterization of a ouabainlike compound from human plasma," Proc. Natl. Acad. Sci. USA 88:6259-6263, Jul. 1991.
Haupert, Jr.; in The Na.sup.+ , K.sup.+ -Pump, Part B: Cellular Aspects; Alan R. Liss, Inc., New York; 1988; pp. 297-320.
Harris et al., TIBTECH, 11: 42-44, 1993.
Waldmann, Science, 252: 1657-1662, 1991.
Foon, Cancer Res, 49: 1621-39, 1989.
Dermer, Biotechnology, 12: 320, 1994.
Peselev Elli
The General Hospital Corporation
LandOfFree
Method for treating cardiac malfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cardiac malfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cardiac malfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2077409